

Neuland Laboratories Limited
11th floor (5th level), Phoenix IVY Building,
Plot No.573A-III, Road No.82, Jubilee Hills,
Hyderabad-500033, Telangana, India.



CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

July 31, 2025

To

BSE Limited

Phiroze Jeejeebhoy Towers, 25th Floor, Dalal
Street, Mumbai – 400 001

The National Stock Exchange of India Ltd

Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors at their meeting held on even date, i.e. July 31, 2025 have considered and approved the following:

A. Financial Results

Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30, 2025. A copy of the Unaudited Financial Results for the quarter ended June 30, 2025 together with the limited review reports (Standalone & Consolidated) by the Statutory Auditors of the Company are enclosed herewith.

B. Re-appointment of Dr. Ravi Shankar Gopinath (DIN: 00803847), as an Additional Director of the Company

Appointment of Dr. Ravi Shankar Gopinath (DIN: 00803847), as an Additional Director of the Company, categorized as Independent, on the Board of the Company, for a term of five consecutive years, effective from August 1, 2025, basis the recommendation of the Nomination and Remuneration Committee, subject to the approval of the shareholders of the Company.

The details as required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with respect to the above appointment is enclosed as **Annexure A**.

The meeting of Board of Directors of the Company commenced at 1:30 p.m. and concluded at 3.47 p.m.


The above information will also be available on the website of the Company at www.neulandlabs.com.

This is for your information and records.

Thanking you,

Yours Sincerely,

For Neuland Laboratories Limited


Sarada Bhamidipati
Company Secretary




Encl: As above

Independent Auditor's Review Report on Standalone unaudited financial results of Neuland Laboratories Limited for the quarter ended June 30, 2025, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Neuland Laboratories Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Neuland Laboratories Limited ("the Company") for the quarter ended June 30, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS 34") and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Prakash Chandra Bhutada
Partner
Membership No.: 404621

UDIN: 25404621BMOJFM2464

Place: Hyderabad
Date: July 31, 2025



CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

NEULAND LABORATORIES LIMITED
11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III,
Road No 82, Jubilee Hills, Hyderabad - 500033
STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	Quarter Ended			Year Ended
		30.06.2025 (Unaudited)	31.03.2025 (Refer Note 6)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Income				
	(a) Revenue from operations	29,275.27	32,836.00	43,960.17	147,683.73
	(b) Other income	785.59	746.38	480.70	2,050.86
	Total Income	30,060.86	33,582.38	44,440.87	149,734.59
2	Expenses				
	(a) Cost of materials consumed	16,148.04	14,124.15	15,495.13	57,480.68
	(b) Changes in inventories of finished goods and work-in-progress	(4,793.65)	(1,434.14)	2,193.17	1,283.12
	(c) Employee benefits expense	7,088.24	6,419.13	7,096.74	26,139.85
	(d) Finance costs	458.33	234.60	267.05	829.59
	(e) Depreciation and amortisation expenses	2,018.72	1,689.04	1,627.88	6,554.19
	(f) Manufacturing expenses	3,937.48	4,509.03	3,615.44	16,287.00
	(g) Other expenses	3,465.90	4,142.39	3,177.16	14,263.19
	Total expenses	28,323.06	29,684.20	33,472.57	122,837.62
3	Profit before exceptional items and tax (1-2)	1,737.80	3,898.18	10,968.30	26,896.97
4	Exceptional items (Refer Note 4)	-	-	2,062.56	7,640.36
5	Profit before tax (3+4)	1,737.80	3,898.18	13,030.86	34,537.33
6	Tax expense				
	(a) Current tax	436.68	593.67	3,058.04	7,365.30
	(b) Deferred tax	(69.64)	531.12	138.89	1,229.49
7	Profit for the period / year (5-6)	1,370.76	2,773.39	9,833.93	25,942.54
8	Other comprehensive income (net of taxes)				
	Items not to be reclassified to profit or loss				
	Re-measurement gain/(loss) on defined benefit plans	-	(3.22)	-	(56.30)
	Equity instruments through other comprehensive income	-	26.63	1.36	27.99
	Tax on items that will not be reclassified to profit or loss	-	(5.90)	-	7.12
	Total comprehensive income	1,370.76	2,790.90	9,835.29	25,921.35
9	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
10	Other equity (excluding revaluation reserve)	-	-	-	150,405.12
11	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)				
	(a) Basic (Refer Note 5)	10.68	21.62	76.65	202.20
	(b) Diluted (Refer Note 5)	10.68	21.62	76.65	202.20
	See accompanying notes to the financial results				

NOTES:

- The financial results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 31, 2025.
- The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".
- During the previous year, the Company has fully transferred an investment property located in Nanakramguda, Hyderabad, Telangana, through perpetual lease, resulting in total profit of ₹ 7,640.36 lakhs (For the quarter ended June 30, 2024: ₹ 2,062.56 lakhs) being the profit is exceptional in nature, it has been disclosed as a separate line item.
- The EPS for quarters has not been annualised.
- The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year March 31, 2025 and year to date figures upto the third quarter ended December 31, 2024.

Place: Hyderabad
Date: July 31, 2025



For Neuland Laboratories Limited



Dr. D R Rao
Executive Chairman
(DIN 00107737)



Independent Auditor's Review Report on consolidated unaudited financial results of Neuland Laboratories Limited for the quarter ended June 30, 2025, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Neuland Laboratories Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of **Neuland Laboratories Limited** ("the Holding Company"), its subsidiaries, (the Holding Company and its subsidiaries together referred to as ("the Group")) for the quarter ended June 30, 2025 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS 34") and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.


4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Neuland Laboratories K.K., Japan	Wholly Owned Subsidiary
2	Neuland Laboratories Inc., USA	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The Statement includes the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflects total revenue of Rs. 458.26 Lakhs, total net profit after tax of Rs. 19.24 Lakhs and total comprehensive income of Rs. 29.16 Lakhs for the quarter ended June 30, 2025, as considered in the Statement. This interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, this interim financial information are not material to the Group.

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W


Prakash Chandra Bhutada
Partner
Membership No.: 404621
UDIN: 25404621BMOJFN1156
Place: Hyderabad
Date: July 31, 2025



<p style="text-align: center;">NEULAND LABORATORIES LIMITED 11th Floor (5th Office Level), Phoenix IVY Building, Plot No. 573A-III, Road No 82, Jubilee Hills, Hyderabad - 500033 STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025</p>				
(Amount in lakhs of ₹, unless otherwise stated)				
Sl. No.	Particulars	Quarter Ended		Year Ended
		30.06.2025 (Unaudited)	31.03.2025 (Refer Note 7)	30.06.2024 (Unaudited)
1	Income			31.03.2025 (Audited)
	(a) Revenue from operations	29,275.27	32,836.00	43,960.17
	(b) Other income	785.59	746.43	480.70
	Total Income	30,060.86	33,582.43	44,440.87
2	Expenses			
	(a) Cost of materials consumed	16,148.04	14,124.15	15,495.13
	(b) Changes in inventories of finished goods and work-in-progress	(4,793.65)	(1,434.14)	2,193.17
	(c) Employee benefits expense	7,346.51	6,645.75	7,313.79
	(d) Finance costs	458.49	234.67	267.05
	(e) Depreciation and amortisation expenses	2,018.95	1,689.19	1,627.99
	(f) Manufacturing expenses	3,937.48	4,509.03	3,615.44
	(g) Other expenses	3,188.00	3,883.82	3,006.66
	Total expenses	28,303.82	29,652.47	33,519.23
3	Profit before exceptional items and tax (1-2)	1,757.04	3,929.96	10,921.64
4	Exceptional items (Refer Note 5)	-	-	2,062.56
5	Profit before tax (3+4)	1,757.04	3,929.96	12,984.20
6	Tax expense			
	(a) Current tax	436.68	602.33	3,058.04
	(b) Deferred tax	(69.64)	547.04	138.89
7	Profit for the period / year (5-6)	1,390.00	2,780.59	9,787.27
8	Other comprehensive income (net of taxes)			
	(a) Items not to be reclassified to profit or loss			
	Re-measurement gain/(loss) on defined benefit plans	-	(3.22)	-
	Equity instruments through other comprehensive income	-	26.63	1.36
	Tax on items that will not be reclassified to profit or loss	-	(5.90)	-
	(b) Items to be reclassified to profit or loss			
	Exchange differences in translating the financial statements of foreign operations	9.92	2.85	(2.12)
	Total comprehensive income	1,399.92	2,800.95	9,786.51
9	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05
10	Other equity (excluding revaluation reserve)	-	-	-
11	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)			
	(a) Basic (Refer Note 6)	10.83	21.67	76.28
	(b) Diluted (Refer Note 6)	10.83	21.67	76.28
	See accompanying notes to the financial results			

NOTES:

- The financial results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 31, 2025.
- The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations
- The consolidated financial results include results of the following wholly owned subsidiaries:
(a) Neuland Laboratories Inc., USA
(b) Neuland Laboratories KK., Japan.
- The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".
- During the previous year, the Company has fully transferred an investment property located in Nanakramguda, Hyderabad, Telangana, through perpetual lease, resulting in total profit of ₹ 7,640.36 lakhs (For the quarter ended June 30, 2024: ₹ 2,062.56 lakhs) being the profit is exceptional in nature, it has been disclosed as a separate line item.
- The EPS for quarters has not been annualised.
- The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited figures upto nine months of the relevant financial year.

Place: Hyderabad
Date: July 31, 2025



For Neuland Laboratories Limited

Dr. D R Rao
Executive Chairman
(DIN 00107737)



Annexure A

Details required under Regulation 30 of SEBI Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Details of Dr. Ravi Shankar Gopinath

Sl. No.	Particulars	Remarks
1.	DIN	00803847
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as an Additional Director of the Company, categorized as Independent with effect from August 1, 2025
3.	Date of appointment and term of appointment	For a term of five consecutive years, effective from August 1, 2025 to July 31, 2030
4.	Brief Profile	<p>Dr. Ravi Shankar Gopinath (aged 60 years) has over 30 years of diverse global experience and a proven track record in setting up and scaling high growth and profitable businesses, through organic and inorganic strategies. Highly experienced in multi-cultural and highly globalized corporate environments. As a non-executive director on the Boards of listed companies, brings to bear extensive general management experience in strategy formulation and execution, the application of digital technologies, driving operational excellence, M&A transactions and integration, organization change and leadership development in a global context.</p> <p>He holds a Ph.D. in Chemical Engineering from Rensselaer Polytechnic Institute, New York and Masters in Chemical Engineering from IIT, Bombay.</p>
5.	Disclosure of relationships between directors	None
6.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/ 14/ 2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/24, dated 20th June 2018	Dr. Ravi Shankar Gopinath is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

